BOSTON, March 22, 2021 /PRNewswire/ -- Oncopeptides AB
(publ) (Nasdaq Stockholm: ONCO), a global biotech
company focused on the development of therapies for
difficult-to-treat hematological diseases, today announced
that PEPAXTO® (melphalan flufenamide) has been added to
the Multiple Myeloma Clinical Practice
Guidelines of the National Comprehensive Cancer
Network® (NCCN) in Oncology. PEPAXTO, in combination with
dexamethasone, was granted accelerated approval by the FDA on
February 26, 2021, for the treatment
of adult patients with relapsed or refractory multiple myeloma who
have received at least four prior lines of therapy and whose
disease is refractory to at least one proteasome inhibitor, one
immunomodulatory agent, and one CD38-directed monoclonal
antibody.
"The NCCN Guidelines® are a trusted resource for clinicians in
the management of oncology patients," said Mohamed Ladha, General Manager of the U.S.
Business Unit, at Oncopeptides. "We are truly honored that PEPAXTO
has been added to these esteemed Guidelines and we thank NCCN for
this recognition."
NCCN is an alliance of 30 cancer centers in the United States. Over the past 25 years,
NCCN has developed an integrated suite of tools to improve the
quality of cancer care. The NCCN Clinical Practice Guidelines in
Oncology (NCCN Guidelines®) document evidence-based,
consensus-driven management to ensure that all patients receive
preventive, diagnostic, treatment, and supportive services that are
most likely to lead to optimal outcomes. To learn more about the
NCCN Guidelines® and Clinical Resources you may
visit www.nccn.org
Limitation of Use
PEPAXTO is not indicated and is not recommended for use as a
conditioning regimen for transplant outside of controlled clinical
trials.
To view the full prescribing information please visit
https://pepaxto.com/docs/pepaxto_pi.pdf
About Oncopeptides
Oncopeptides is a global biotech company committed to developing
targeted therapies for patients facing hard-to-treat hematological
diseases. Oncopeptides has one U.S. FDA approved product,
PEPAXTO® (melphalan flufenamide), known during clinical
development as melflufen. PEPAXTO is approved for patients with
triple-class refractory multiple myeloma and was evaluated in
several clinical studies including the pivotal Phase 2 HORIZON
study and is currently being evaluated in the confirmatory Phase 3
OCEAN study. Oncopeptides' headquarters is in Stockholm, Sweden, with a U.S. headquarters in
Boston, Massachusetts. In addition
to Boston, Oncopeptides has a
footprint in Los Altos,
California, another U.S. biotech hub. For more information,
please visit our corporate website at https://oncopeptides.se/en/.
You may also visit our U.S. website at
https://www.oncopeptides-us.com/en and follow us on our U.S.
social media channels, Twitter and LinkedIn.
PEPAXTO® is a trademark of Oncopeptides AB (publ).
For more information, please contact:
Sarah Connors, Head of U.S.
Communications, Oncopeptides, Inc.
E-mail: sarah.connors@oncopeptides.com
Cell phone: 508-654-2277
Linda Holmström, Director Investor Relations, Oncopeptides AB
(publ)
E-mail: linda.holmstrom@oncopeptides.com
Cell phone: + 46 70 873 40 95
This information was brought to you by Cision
http://news.cision.com
The following files are available for download:
https://mb.cision.com/Main/20208/3311249/1390400.pdf
|
US Release:
Oncopeptides Announces National Comprehensive Cancer Network® Adds
PEPAXTO® (melphalan flufenamide) to Its Multiple Myeloma Clinical
Practice Guidelines
|
View original
content:http://www.prnewswire.com/news-releases/oncopeptides-announces-national-comprehensive-cancer-network-adds-pepaxto-melphalan-flufenamide-to-its-multiple-myeloma-clinical-practice-guidelines-301252780.html
SOURCE Oncopeptides AB